Clear Gene

Clear Gene is a biotechnology company that helps detect cancer that remains after treatment, known as residual disease. Using genomics and machine learning, the company focuses on improving detection for solid tumors such as breast cancer. Clear Gene’s software and test kits help clinical labs run more samples at lower cost using their existing equipment.

Investment Details

Portfolia Fund

Funding Round

Seed

Milestones

Funded in 2025

About the Founder

Dr. Brandon Steelman

Dr. Brandon Steelman is the founder of Clear Gene, which he started in 2012 to develop RNA-based diagnostic tests. His work combines molecular biology and data science to improve clinical outcomes in areas such as cancer and infectious disease.

Real Investors. Real Outcomes.

“I have learned so much about leadership, financial well-being, and the power of connection from the amazing community of women at Portfolia.”

Peggy Northrop

CEO of Watermark and Former Editor-in-Chief of More Magazine, Connecticut

“I love the concept of being able to invest and collaborate with others, mitigating my own risk by investing in a portfolio. It lets me see more deals in the pipeline.”

Chantell Preston

Healthcare Executive, Houston, TX

“I joined because I was excited that the model was more like a mutual fund and offered exposure to so many companies and opportunities to further learning.”

Namrita Kapur

Fellow, Yale School of Management, Boston, MA